MA Private Wealth Sells 269 Shares of Johnson & Johnson (NYSE:JNJ)

MA Private Wealth reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,642 shares of the company’s stock after selling 269 shares during the period. MA Private Wealth’s holdings in Johnson & Johnson were worth $418,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of JNJ. Beam Wealth Advisors Inc. boosted its position in Johnson & Johnson by 12.2% during the first quarter. Beam Wealth Advisors Inc. now owns 2,869 shares of the company’s stock worth $454,000 after purchasing an additional 311 shares during the period. HB Wealth Management LLC raised its holdings in Johnson & Johnson by 10.4% during the 1st quarter. HB Wealth Management LLC now owns 193,571 shares of the company’s stock valued at $30,621,000 after acquiring an additional 18,172 shares during the period. Turtle Creek Wealth Advisors LLC lifted its position in shares of Johnson & Johnson by 50.8% during the first quarter. Turtle Creek Wealth Advisors LLC now owns 4,140 shares of the company’s stock worth $655,000 after acquiring an additional 1,394 shares in the last quarter. Valued Wealth Advisors LLC boosted its holdings in shares of Johnson & Johnson by 17.1% in the first quarter. Valued Wealth Advisors LLC now owns 590 shares of the company’s stock worth $93,000 after acquiring an additional 86 shares during the period. Finally, Violich Capital Management Inc. grew its position in shares of Johnson & Johnson by 4.5% in the first quarter. Violich Capital Management Inc. now owns 96,736 shares of the company’s stock valued at $15,303,000 after purchasing an additional 4,162 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ traded up $0.27 during midday trading on Friday, hitting $145.96. The stock had a trading volume of 2,481,476 shares, compared to its average volume of 7,315,834. The company has a market cap of $351.28 billion, a P/E ratio of 9.03, a price-to-earnings-growth ratio of 2.42 and a beta of 0.52. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The business has a fifty day moving average of $147.94 and a 200 day moving average of $153.79. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.68 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.40%. The ex-dividend date was Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is 30.92%.

Analysts Set New Price Targets

Several brokerages have commented on JNJ. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Monday. Bank of America reduced their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday, June 30th. Finally, HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price objective for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Eight research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $174.07.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.